GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Study To Determine The Effect Of SB-480848 On Asthma
- Conditions
- Atherosclerosis
- First Posted Date
- 2006-08-24
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 67
- Registration Number
- NCT00368576
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
Effects Of Atorvastatin On Macrophage Activity And Plaque Inflammation Using Magnetic Resonance Imaging
- Conditions
- Atherosclerotic Carotid DiseaseAtheromaAtherosclerosis
- First Posted Date
- 2006-08-24
- Last Posted Date
- 2015-04-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 47
- Registration Number
- NCT00368589
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom
Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung CancerLung Cancer, Non-Small Cell
- Interventions
- First Posted Date
- 2006-08-23
- Last Posted Date
- 2012-06-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 35
- Registration Number
- NCT00367679
- Locations
- 🇪🇸
GSK Investigational Site, Barcelona, Spain
Rosiglitazone-Metformin Combination Versus Metformin-Sulfonylurea Combination On Beta-Cell Function In Type 2 Diabetes
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2006-08-22
- Last Posted Date
- 2010-07-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 84
- Registration Number
- NCT00367055
Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting
- Conditions
- VomitingNauseaNausea and Vomiting, Chemotherapy-Induced
- Interventions
- First Posted Date
- 2006-08-21
- Last Posted Date
- 2012-09-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1840
- Registration Number
- NCT00366834
- Locations
- 🇬🇧
GSK Investigational Site, Shrewsbury, United Kingdom
To Evaluate Immunogenicity & Safety of GSK Bio's DTPa-HBV-IPV/Hib (Mixed Vaccine) and DTPa-IPV/Hib + HBV Vaccines
- Conditions
- Hepatitis B
- First Posted Date
- 2006-08-21
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 150
- Registration Number
- NCT00366366
Effectiveness Of The Drug GSK189254 In Treating Patients With Narcolepsy
- Conditions
- Narcolepsy
- First Posted Date
- 2006-08-18
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 69
- Registration Number
- NCT00366080
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
SPECT Investigation Of The NMDA Receptor System In Healthy Volunteers And Patients With Schizophrenia
- Conditions
- Schizophrenia
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2016-01-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 55
- Registration Number
- NCT00364429
- Locations
- 🇪🇸
GSK Investigational Site, Barcelona, Spain
GSK159802 In Healthy Male Subjects And Asthmatics
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2017-09-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 43
- Registration Number
- NCT00364273
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's
- Conditions
- Parkinson's DiseaseDyskinesiasParkinson Disease
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 209
- Registration Number
- NCT00363727
- Locations
- 🇺🇸
GSK Investigational Site, Madison, Wisconsin, United States